Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab for Plaque Psoriasis with Coexisting NAFLD (pINPOINt)
NCT04237116Phase 3Terminated
- Sponsor
- Novartis
- Start
- Feb 2020
- Primary completion
- Jun 2021
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of secukinumab in plaque psoriasis, non-alcoholic fatty liver disease (NAFLD), sponsored by Novartis. Started Feb 2020; status: terminated.
02
Drugs
secukinumab
03
Conditions
plaque psoriasisnon-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT04237116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04237116.